Shanghai, China - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow", stock code: 02160.HK) announced that its self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (hereinafter referred to as "VitaFlow Liberty^®"), a new generation product for Transcatheter Aortic Valve Implantation (TAVI), has been approved by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

Shanghai, China, 28 December 2021 — MicroPort^® CardioFlow Medtech Corporation (MicroPort^® CardioFlow) recently announced that its latest transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has completed the submission of applications materials for the EU CE certification.

Shanghai, China, 5 November 2021 — MicroPort^® CardioFlow Medtech Corporation (CardioFlow Medtech) hosted a symposium for its next-generation transcatheter aortic valve implantation (TAVI) product, the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™), during the 32nd Great Wall International Congress of Cardiology (GW-ICC) and Asia Heart Society Congress. The event brought together experts in the field of structural heart disease to share their experience on the clinical application of VitaFlow Liberty™.